

Evaluation of Microalgae for use as Nutraceuticals and Nutritional Supplements

West M. Bishop^{1*} and Heidi M. Zubeck²

¹Algae and Aquatic Research Scientist: SePRO Corporation, SePRO Research and Technology Campus, Whitakers, NC, USA

²Doctor of Chiropractic: Tri-County Clinic of Chiropractic, Vidalia, GA, USA

Abstract

As proper nourishment is a growing concern with increasing world populations, sustainable sources of nutritional value are needed. Due to the diverse nutritional components algae can produce and concentrate, along with their simple and rapid growth characteristics, these autotrophic organisms are exceedingly desired for use in nutraceuticals and nutritional supplements. Many types of algae have documented health benefits from strengthening the immune system to fighting cancer and heart disease. Information presented in this article was mined from quality, peer-reviewed published literature, technical reports and books. This review evaluates the use of *Chlorella*, *Dunaliella*, *Haematococcus*, *Aphanizomenon*, and *Spirulina* as nutraceuticals and nutritional supplements, in terms of production, nutritional components, and documented health benefits.

Keywords: Algae; Nutraceuticals; Health benefits; Nutritional supplements

Introduction

Nutraceuticals are nutrients from food or food products that not only supplement the diet but also facilitate the prevention or treatment of a disease and/or disorder [1]. There are over 470 nutraceutical and functional food products commercially available with researched health benefits [2]. An increased global interest has arisen in these substances due to their documented role in health enhancement [3]. The health-seeking consumer trend has intensified the use of products aimed at promoting health as well as treating potential fatal ailments (i.e. heart disease, cancer, Parkinson's disease etc.). The current estimated global market size for nutraceutical products is 30 to 60 billion dollars, primarily in the United States, Japan, and Europe, with a potential short-term growth market demand of over 197 billion dollars [4]. With the increase in demand for nutraceuticals and food supplements, organisms that can rapidly produce nutritional compounds are desired.

Algae are a diverse group of autotrophic organisms that have the ability to grow rapidly, efficiently use light energy, fix atmospheric CO₂, and produce more biomass per acre than vascular plants [5]. Algae have been used as a food source and for treatment of various ailments for over two thousand years [6,7]. Algae can form numerous compounds that are currently present in nutraceuticals and have the potential to become more intensively exploited. Different types of algae, specifically microalgae, that could become more prevalent in food supplements and nutraceuticals are *Nostoc*, *Botryococcus*, *Anabaena*, *Chlamydomonas*, *Scenedesmus*, *Synechococcus*, *Parietochloris*, and *Porphyridium* etc. due to the capability of producing necessary vitamins including: A (Retinol), B₁ (Thiamine), B₂ (Riboflavin), B₃ (Niacin), B₆ (Pyridoxine), B₉ (Folic acid), B₁₂ (Cobalamin), C (L-Ascorbic acid), D, E (Tocopherol), and H (Biotin). Also, these organisms concentrate essential elements including: Potassium, Zinc, Iodine, Selenium, Iron, Manganese, Copper, Phosphorus, Sodium, Nitrogen, Magnesium, Cobalt, Molybdenum, Sulfur and Calcium. Algae are also high producers of essential amino acids and Omega 6 (Arachidonic acid) and Omega 3 (docosahexaenoic acid, eicosapentaenoic acid) fatty acids [8]. Due to their abundant production of beneficial compounds and nutritive contents, the market for increased algae production for nutraceuticals is lucrative and imminent.

As proper nourishment is a growing concern with increasing world populations, easy to produce and cost-effective sources that can rapidly produce large amounts of nutritional value are needed. Algae can provide a significant source of a diverse number of critical nutrients to support human health. Algae are ubiquitous throughout the world and have persisted and thrived in numerous types of environments. The adaptations they have developed and propagated are accompanied by benefits to organisms up the food chain. Many of these unique characteristics (carotenoids, micronutrient accumulation, amino acids etc.) have led to an extensive base of compounds that are critical in human health. Discovering of these algae and contained compounds is in its infancy, though numerous beneficial products are currently present. The goal of this article is to review the current status of nutraceutical products and food supplements when it regards common cultured microalgae production and use as well as to outline the positive health benefits documented from these algae. The specific objectives of this research were to (1) Review common types of microalgae (i.e., *Chlorella*, *Dunaliella*, *Haematococcus*, *Aphanizomenon*, and *Spirulina*) currently used in nutraceuticals; (2) Describe their characteristics, nutritional benefits, and possible side effects; and (3) Evaluate the potential for increased nutraceutical production through currently used algae as well as up and coming sources.

Materials and Methods

The literature selected for use in this review was obtained through database and internet search engines (i.e., Web of Science, BioOne, Google Scholar). No internet citations are present; all information was mined from peer-reviewed published literature, technical reports

***Corresponding Author:** West M. Bishop, 16013 Watson Seed Farm Rd., Whitakers, NC 27891, USA, Tel: 252-801-1623, Fax: 252-437-3280; E-mail: westb@sepro.com

Received May 19, 2012; Accepted June 20, 2012; Published June 25, 2012

Citation: Bishop WM, Zubeck HM (2012) Evaluation of Microalgae for use as Nutraceuticals and Nutritional Supplements. J Nutr Food Sci 2:147. doi:10.4172/2155-9600.1000147

Copyright: © 2012 Bishop WM, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

and books. Sources were selected based upon their quality of research and content. Only studies with an appropriate experimental design and valid measurements of presented data were used. Due to the vast amount of published literature on this topic and the limited number of articles that can be cited, only a fraction of the available literature was selected for this article.

Results

Chlorella

Chlorella is a unicellular, green alga found in many aquatic systems and is widely sold as a health food, food supplement, and nutraceutical [9]. The United States, Japan, China, Taiwan, and Indonesia produce over 2500 tons of dried *Chlorella* each year [10]. It is considered an important functional food and source of nutrients in many areas due to its abundance and positive health effects. *Chlorella* is sold and distributed by numerous vendors such as Lucky Vitamin™, Prime Chlorella™ Distribution Inc., Sun Chlorella, HerbMark, Puritan's Pride and more. Due to its rapid growth characteristics and nourishing qualities, *Chlorella* will likely continually supplement our dietary needs, as it has for many decades.

Chlorella is composed of 55-67% protein, 1-4% chlorophyll, 9-18% dietary fiber and numerous minerals and vitamins [11]. The protein of *Chlorella* contains all essential amino acids required for the nutrition of heterotrophic organisms. Porphyrin rings in chlorophyll or glutathione induced pathway production by vitamin B₁₂ in *Chlorella* [12] have been shown to detoxify problematic metals and pesticides [11,13]. *Chlorella* is a large producer of lutein, which has been shown to prevent and treat macular degeneration and contains anti-cataract properties [14]. Extracts of *Chlorella* have been documented as possessing diverse antitumor [15,16], antioxidant [17], anti-inflammatory [18], and antimicrobial activities [19]. *Chlorella* is able to decrease blood pressure, lower cholesterol levels, accelerate wound healing, and enhance the immune system [20]. It also has the potential to relieve symptoms and improve quality of life in people with fibromyalgia, hypertension, or ulcerative colitis [21,22]. The presence of aortic atheromatous lesions was significantly inhibited and low-density lipoprotein (LDL) cholesterol levels were greatly suppressed upon consumption of *Chlorella* [23].

Chlorella consumption as a nutritional product has initiated investigations to its possible side effects. Some consumers have indicated a potential correlation between some brands of *Chlorella* tablets and nausea, vomiting, and other gastrointestinal issues. Poor digestibility if not processed efficiently has been documented and may lead to certain gastrointestinal issues [24]. *Chlorella* tablets have been indicated in the causation of acute tubulointerstitial nephritis often resulting in renal failure [25]. *Chlorella* has been labeled as a weak allergen and may be of clinical significance to certain types of people [24]. Aside, from the potential for negative effects of *Chlorella* supplementation, culturing may prove challenging as well. *Chlorella* cultivation systems may be extremely costly and often become contaminated by other algae or bacteria, thereby hindering production [20].

Dunaliella

Dunaliella (*D. salina* dominant in nutraceutical production) is a unicellular, green alga that produces large amounts of beta carotene, glycerol, and protein that can easily be extracted through its thin cell wall [26,27]. Due to its unique growth environment and halo tolerance of saline conditions (up to 100 g NaCl/L) it does not utilize waters appropriate for agricultural and domestic uses. Also, few other

organisms can survive in such conditions so the opportunity for contamination by other algae, fungi, animals and bacteria is minimal and open outdoor cultures can be utilized [28-30]. Global production of *Dunaliella* is estimated to be 1,200 tons dry weight per year [31]. The dominant companies that produce *Dunaliella*, mainly for beta-carotene production, are located in Israel, China, United States, and Australia and include: Betatene, Western Biotechnology, AquaCarotene LTD, Cyanotech Corp., Nature Beta Technologies and more [32].

Dunaliella produces numerous carotenoid pigments with the dominant being beta-carotene and smaller amounts of alpha-carotene, lutein, and lycopene [27]. Some strains of *Dunaliella* contain up to 14% dry weight beta-carotene [33]. The total carotenoid content of *Dunaliella* varies with growth conditions, although the ideal environment can yield around 400 mg beta-carotene/m² of cultivation area [34]. Carotenoids from *Dunaliella* are potent free radical scavengers that reduce levels of lipid peroxidation and enzyme inactivation, thereby restoring enzyme activity [27]. Beta-carotene is an antioxidant that can trap reactive oxygen species involved in the aging process [35,36]. Studies have shown beta-carotene to prevent cancer of various organs like lungs, stomach, cervix, pancreas, colon, rectum, breast, prostate and ovary by means of antioxidant activity [37]. It has also been shown to promote regression of certain types of cancer [38]. Beta-carotene from *Dunaliella* can positively influence intracellular communication [39], immune response [40], and protection against many types of neoplasms [41]. Supplements of *Dunaliella* have also shown excellent hepatoprotective effects and reduced the occurrence of liver lesions [42].

Despite the advancement in the production of beta-carotene from natural sources like *Dunaliella*, more than 90% of commercialized beta-carotene is produced synthetically [33]. However, natural (i.e., produced by organisms) beta-carotene has a higher bioavailability compared to synthetically manufactured beta-carotene [43]. The activity and amount of the antioxidant enzymes catalase, peroxidase, and superoxide dismutase were significantly greater in naturally produced beta-carotene from *Dunaliella* compared to synthetic [27]. The potential health benefits from *Dunaliella* are numerous and little data are present on risks associated with consumption of supplements containing this alga. Multigenerational studies with rats consuming up to 10% *Dunaliella* in their diets showed no significant negative effects and was indicative of the safety of *Dunaliella* for human consumption [44].

Haematococcus

Haematococcus (*H. pluvialis* predominantly produced) is a unicellular, green alga that is a common component of nutraceuticals, pharmaceuticals, cosmetics, aquaculture, and numerous food products [45]. Approximately 300 tons dry weight of *Haematococcus* is produced annually in the United States, India and Israel [46]. Under conditions not favorable for cell growth *Haematococcus* goes into a resting stage, indicated by the pigment astaxanthin, making the cells appear red. Astaxanthin sells for \$2,500 per kilogram dry weight with an annual worldwide market estimated at \$200 million; although 95% of this market consumes synthetically derived astaxanthin [45,47]. Numerous patents exist on the usages of it, primarily in the arenas of food and health. *Haematococcus* is cultivated commercially in large-scale outdoor systems and controlled photobioreactors. Companies that mass produce *Haematococcus*, predominantly for astaxanthin, include: Cynotech Corporation, Parry Nutraceuticals, BioReal, Inc., Fuji Health Science, Valensa International, Alga Technologies, and Aquasearch Inc.

Despite the other vitamins and minerals in *Haematococcus*,

the primary nutraceutical market is incorporated in astaxanthin. *Haematococcus* is the largest natural source of astaxanthin, which comprises 1.5-3% of its dry weight [47]. Astaxanthin is a carotenoid pigment with antioxidant activity at least 10 times stronger than beta-carotene and 1000 times more effective than vitamin E [48,49]. It is effective at decreasing arterial blood pressure, plasma levels of triglycerides and non-esterified fatty acids [50]. Astaxanthin has important metabolic functions in humans like protection against oxidation of essential polyunsaturated fatty acids, protection against UV radiation effects, enhanced vision, immune response, pigmentation and reproductive behavior [51]. This pigment possesses anti-oxidative [52], anti-cancer [53], anti-inflammatory, and anti-bacterial activities [54]. Astaxanthin is also useful for prevention and treatment of neural damage associated with age-related macular degeneration and effective at treating Alzheimer's disease, Parkinson's disease, spinal cord damage, and other central nervous system injuries [55,56].

Haematococcus has not been reported in any discovered peer reviewed literature to possess negative consequences upon ingestion. Animal studies with rats revealed no adverse effects of consuming 5 to 18 g/kg/day [57]. *Haematococcus* algal extract containing astaxanthin was tested on humans for eight weeks and no significant differences were measured for adverse clinical parameters [58]. Further human studies at exposures of 20 mg/day for four weeks revealed no negative effects on blood chemistry, hematology, or other adverse experiences during treatment [59]. Also, no negative effects were measured on human health following exposures to pharmaceuticals containing dietary astaxanthin [60]. *Haematococcus pluvialis* was approved for marketing as a new dietary ingredient in the United States by the Food and Drug Administration (FDA) in August 1999. No confirmed reports or documentation could be found regarding non-compliance with safety trial parameters in astaxanthin exposures [61].

Aphanizomenon

Aphanizomenon is a prokaryotic cyanobacterium (blue-green alga) commonly found in freshwater systems throughout the world. Approximately 500 tons of dried *Aphanizomenon* is produced annually for use in food and pharmaceutical products [31]. This alga has been cultivated for consumption for many years and is currently being produced in many countries. The dominant production source of *Aphanizomenon* in North America is Upper Klamath Lake, Klamath Falls, Oregon and currently constitutes a significant part of the health food supplement industry throughout North America [62]. The primary companies responsible for the harvesting and distribution of supplements containing *Aphanizomenon* are Cell Tech International Inc., Life Enthusiast Co-op, AquaSource and Klamath Valley Botanicals, Inc.

Aphanizomenon contains a significant amount of chlorophyll (1-2% dry weight) which is shown to stimulate liver function and increase bile secretion [63]. C-Phycocyanin, another light-harvesting pigment it contains, has antioxidant and anti-inflammatory properties [64]. *Aphanizomenon* also has high hypo cholesterolemic activity, significantly greater than soybean oil, which causes a decrease in blood cholesterol and triglyceride levels [65,66]. *Aphanizomenon* is a large producer of polyunsaturated fatty acids (i.e., omega 3 and omega 6), a deficiency of which has been linked to immunosuppression [67], arthritis [68], cardiovascular diseases [69,70], mental health issues [70,71], and dermatological problems [72]. Additionally, components of this alga have been shown to decrease certain cancer risks [73], inflammation [68], and prevent platelet accumulation [74]. Manoukian et al. [75] found *Aphanizomenon* to increase natural killer cells that

induce programmed cell death in virus-infected and cancerous cells and Ostensvik et al. [76] identified antibacterial properties. There are also reports of improved behavior and attention span in humans that consume *Aphanizomenon* [62,77].

There has been some interest in the possible negative health effects of consuming *Aphanizomenon*. The primary concerns address toxin production and exposure upon consumption. *Aphanizomenon flos-aquae*, the dominant species used in production has not been shown to produce hepatotoxins (microcystins), although can produce neurotoxins (anatoxin and saxitoxin; [78,79]). *Aphanizomenon* often grows amongst other toxin producing cyanobacteria including *Anabaena* and *Microcystis* that could be harvested unknowingly and contribute to toxin loads including microcystins and neurotoxins [79]. However, with extensive studies on the possible exposures and responses little risk has been observed in current nutritional supplements. Schaeffer et al. [62] found no growth depression, organ malfunction or other deleterious effects on adult mice and no effects on fetus or neonate development with exposures of $\leq 333 \mu\text{g}$ microcystin-LR/kg body weight/day. Concentrations of constituents that may pose risks upon exposure should be evaluated prior to using any product.

Spirulina

Spirulina is a prokaryotic cyanobacterium that has been commercially produced for over thirty years for uses including: fish food, vitamin supplements, food dyes, aquaculture, pharmaceuticals and nutraceuticals [80,81]. Approximately 3,000 tons dry weight is currently produced annually in the United States, Thailand, India, Taiwan, China, Pakistan, and Burma [31,82,83]. *Spirulina* is manufactured by a variety of companies some of which include: Puritan's Pride, Springtime Inc., Valley Naturals, Bio-Alternatives, and Watershed Wellness Center. This alga is thought of as a super food and is widely cultured, primarily in specifically designed raceway ponds and photobioreactors, to meet the current demand.

Spirulina is a rich source of nutrients such as B vitamins, phycocyanin, chlorophyll, vitamin E, omega 6 fatty acids and numerous minerals [84]. *Spirulina* is 60-70% protein by weight (including many amino acids) and contains up to 10 times more beta-carotene than carrots per unit mass [85]. *Spirulina* has assisted in health areas like weight loss [86], diabetes [87], high blood pressure and hypertension [88]. It has well documented antiviral [69,70,89], and anticancer properties [90-92]. *Spirulina* can also enhance the phagocytic activity in macrophages and produce antigen-specific antibody production to help treat depression and attention-deficit hyperactivity disorder [71,93,94]. *Spirulina* positively affects cholesterol metabolism by increasing HDL levels, which can lead to healthy cardiovascular functions [95]. Romay et al. [64] described the antioxidant and anti-inflammatory properties of C-phycocyanin, which is a prevalent pigment in *Spirulina*. Tsuchihashi et al. [96] showed a significant increase in the bacteria *Lactobacillus* in rats following *Spirulina* amendments in their diet; which if occurred in humans would improve digestion, food absorption, and stimulate the immune system to help fight infections [97].

Some question has been raised on the digestion capacity and bioavailability of nutrients like vitamin B₁₂ from *Spirulina* [98]. However, efficient processing claims to release nutrients into a digestible form for humans. Some *Spirulina* supplements have been shown to contain traces of the toxin microcystin due to invasion of other algae (like *Microcystis* spp.) in culturing areas, which acts primarily on decreasing liver function and could cause liver cancer and other diseases [99]. Also, since *Spirulina* can concentrate elemental constituents it may

Component	<i>Spirulina</i>	<i>Dunaliella</i>	<i>Haemato-coccus</i>	<i>Chlorella</i>	<i>Aphanizo-menon</i>
Protein	63	7.4	23.6	64.5	1.0
Fat	4.3	7.0	13.8	10.0	3.0
Carbohydrates	17.8	29.7	38.0	15.0	23.0
Chlorophyll	1.15	2.2	0.4 (red), 1.1 (green)	5.0	1.8
Magnesium	0.319	4.59	1.14	0.264	0.2
Beta-Carotene	0.12	1.6	0.054	0.086	0.42
Vitamin B ₁ (Thiamin)	0.001	0.0009	0.00047	0.0023	0.004
Vitamin B ₂ (Riboflavin)	0.0045	0.0009	0.0017	0.005	0.0006
Vitamin B ₃ (Niacin)	0.0149	0.001	0.0066	0.025	0.013
Vitamin B ₅ (Pantothenic acid)	0.0013	0.0005	0.0014	0.0019	0.0008
Vitamin B ₆ (Pyridoxine)	0.00096	0.0004	0.00036	0.0025	0.0013
Vitamin B ₉ (Folic Acid)	0.000027	0.00004	0.00029	0.0006	0.0001
Vitamin B ₁₂ (Cobalamine)	0.00016	0.000004	0.00012	0.000008	0.0006

Table 1: Summary of referenced average nutritional compositions of the described microalgae expressed as g per 100 g dry weight.

contain elevated amounts of unnecessary elements like mercury and create potential risks, depending on the growth environment. Some of the potential side effects of *Spirulina* products are diarrhea, nausea, and vomiting. Also, allergic reactions, though rare, may result in insomnia and anxiety [100,101].

Conclusion

As the human population continues to increase, demand for nutritive food and health products increases concomitantly. Sources of nutritive biomass that can meet this demand are pursued rampantly. Algae have shown viability in meeting nutritive demands due to their rapid growth, health benefits, and enriched compounds they produce. Algae have been used for centuries to nourish humans but are now being much more intensely cultured and harvested [102]. The role of algae in human health and nutrition will continually increase with additional research in the areas of health benefits and culturing.

Usage of currently produced algae primarily includes: food, food additives, aquaculture, colorants, cosmetics, pharmaceuticals, and nutraceuticals [103]. Only a small fraction of the total number of algal species is being cultivated for human use. There are likely more species of algae that have not been identified than ones that have and those still numbers in the thousands. Therefore, the potential for algal use in the realms of food consumption, health supplements, energy production, and many more is likely to intensify in the years to come. Geographic uses of algae for human nutrition will parallel distribution and specific growth habitat characteristics and capacity.

Nutraceuticals harness and concentrate the nutritive algal components to increase positive health effects. Some types of algae that are currently mass produced for nutritive and other uses have been discussed and their compositions outlined (Table 1). These algae have been integrated into many nutritional programs throughout the world and likely to increase in human consumption. Increased research and development is constantly being funneled to greater production and use of these algae to meet the ever-growing demand and identify benefits of additional types of algae. The ability of algae to treat and prevent numerous types of serious diseases (especially viral infections, heart disease, and cancer) will undoubtedly continually surge interest and investigation into their value for human health and nutrition.

References

- Kalra EK (2003) Nutraceutical--definition and introduction. AAPS PharmSci 5: E25.
- Eskin NAM, Tamir S (2006) Dictionary of Nutraceuticals and Functional Foods. CRC Press, Boca Raton, FL, USA.
- Rajasekaran A, Sivagnanam G, Xavier R (2008) Nutraceuticals as therapeutic agents: A review. Res J Pharm Tech. 1: 328-340.
- Benkouider C (2005) The World's Emerging Markets. Functional Foods & Nutraceuticals 44: 8-11.
- Shay EG (1993) Diesel fuel from vegetable oils: Status and opportunities. Biomass Bioenergy 4: 227-242.
- Richmond A (1990) Handbook of microalgal mass culture. CRC Press, Boca Raton, FL, USA.
- Gao K (1998) Chinese studies on the edible bluegreen alga, *Nostoc flagelliforme*: a review. J Appl Phycol 10: 37-49.
- Simoons FJ (1991) Food in China: A cultural and historical inquiry. CRC Press, Boca Raton, FL, USA.
- Morita K, Matsueda T, Iida T, Hasegawa T (1999) *Chlorella* accelerates dioxin excretion in rats. J Nutr 129: 1731-1736.
- Gupta R, Mukerji KG (2001) Microbial Technology. Kulbhusan Nangia Ashish Books, Darya Ganj, New Delhi, India.
- Shim JY, Shin HS, Han JG, Park HS, Lim BL, et al. (2008) Protective effects of *Chlorella vulgaris* on liver toxicity in cadmium-administered rats. J Med Food 11: 479-485.
- Kittaka-Katsura H, Fujita T, Watanabe F, Nakano Y (2002) Purification and characterization of a corrinoid compound from *Chlorella* tablets as an algal health food. J Agric Food Chem 50: 4994-4997.
- Arimoto-Kobayashi S, Inada N, Nakano H, Rai H, Hayatsu H (1998) Iron-chlorophyllin-mediated conversion of 3-hydroxyamino-1-methyl-5H-pyrido[4,3-b]indole (Trp-P-2(NHOH)) into its nitroso derivative. Mutat Res 400: 259-269.
- Shibata S, Natori Y, Nishihara T, Tomisaka K, Matsumoto K, et al. (2003) Antioxidant and anti-cataract effects of *Chlorella* on rats with streptozotocin-induced diabetes. J Nutr Sci Vitaminol (Tokyo) 49: 334-339.
- Konishi F, Tanaka K, Himeno K, Taniguchi K, Nomoto K (1985) Antitumor effect induced by a hot water extract of *Chlorella vulgaris* (CE): resistance to Meth-A tumor growth mediated by CE-induced polymorphonuclear leukocytes. Cancer Immunol Immunother 19: 73-78.
- Tanaka K, Tomita Y, Tsuruta M, Konishi F, Okuda M, et al. (1990) Oral administration of *Chlorella vulgaris* augments concomitant antitumor immunity. Immunopharmacol Immunotoxicol 12: 277-291.
- Miranda MS, Sato S, Mancini-Filho J (2001) Antioxidant activity of the microalga *Chlorella vulgaris* cultured on special conditions. Boll Chim Farm 140: 165-168.
- Guzmán S, Gato A, Lamela M, Freire-Garabal M, Calleja JM (2003) Anti-inflammatory and immunomodulatory activities of polysaccharide from *Chlorella stigmatophora* and *Phaeodactylum tricornutum*. Phytother Res 17: 665-670.
- Hasegawa T, Tanaka K, Ueno K, Ueno S, Okuda M, et al. (1989) Augmentation of the resistance against *Escherichia coli* by oral administration of a hot water extract of *Chlorella vulgaris* in rats. Int J Immunopharmacol 11: 971-976.
- Bewicke D, Potter BA (1984) *Chlorella*: the emerald food. Ronin Publishing, Berkeley, CA, USA.
- Merchant RE, Andre CA (2001) A review of recent clinical trials of the nutritional supplement *Chlorella pyrenoidosa* in the treatment of fibromyalgia, hypertension, and ulcerative colitis. Altern Ther Health Med 7: 79-91.
- Sansawa H, Takahashi M, Tsuchikura S, Endo H (2006) Effect of *Chlorella* and its fractions on blood pressure, cerebral stroke lesions, and life-span in stroke-prone spontaneously hypertensive rats. J Nutr Sci Vitaminol (Tokyo) 52: 457-466.
- Sano T, Tanaka Y (1987) Effect of dried, powdered *Chlorella vulgaris* on experimental atherosclerosis and alimentary hypercholesterolemia in cholesterol-fed rabbits. Artery 14: 76-84.

24. Tiberg E, Dreborg S, Björkstén B (1995) Allergy to green algae (*Chlorella*) among children. J Allergy Clin Immunol 96: 257-259.
25. Yim HE, Yoo KH, Seo WH, Won NH, Hong YS, et al. (2007) Acute tubulointerstitial nephritis following ingestion of *Chlorella* tablets. Pediatr Nephrol 22: 887-888.
26. Bental M, Degani H, Avron M (1988) Na-NMR Studies of the Intracellular Sodium Ion Concentration in the Halotolerant Alga *Dunaliella salina*. Plant Physiol 87: 813-817.
27. Chidambara Murthy KN, Vanitha A, Rajesha J, Mahadeva Swamy M, Sowmya PR, et al. (2005) In vivo antioxidant activity of carotenoids from *Dunaliella salina*--a green microalga. Life Sci 76: 1381-1390.
28. Borowitzka MA, Borowitzka LJ (1988) *Dunaliella*. Micro-algal Biotechnology. Cambridge University Press, Cambridge, UK.
29. Pulz O (2001) Photobioreactors: production systems for phototrophic microorganisms. Appl Microbiol Biotechnol 57: 287-293.
30. García-González M, Moreno J, Manzano JC, Florencio FJ, Guerrero MG (2005) Production of *Dunaliella salina* biomass rich in 9-cis-beta-carotene and lutein in a closed tubular photobioreactor. J Biotechnol 115: 81-90.
31. Pulz O, Gross W (2004) Valuable products from biotechnology of microalgae. Appl Microbiol Biotechnol 65: 635-648.
32. Del Campo JA, García-González M, Guerrero MG (2007) Outdoor cultivation of microalgae for carotenoid production: current state and perspectives. Appl Microbiol Biotechnol 74: 1163-1174.
33. Raja R, Hemaiswarya S, Rengasamy R (2007) Exploitation of *Dunaliella* for beta-carotene production. Appl Microbiol Biotechnol 74: 517-523.
34. Finney KF, Pomeranz Y, Bruinsma BL (1984) Use of algae *Dunaliella* as a protein supplement in bread. Cereal Chem 61: 402-406.
35. Burton GW, Ingold KU (1984) beta-Carotene: an unusual type of lipid antioxidant. Science 224: 569-573.
36. Cao G, Prior RL (1998) Comparison of different analytical methods for assessing total antioxidant capacity of human serum. Clin Chem 44: 1309-1315.
37. van Poppel G, Goldbohm RA (1995) Epidemiologic evidence for beta-carotene and cancer prevention. Am J Clin Nutr 62: 1393S-1402S.
38. Schwartz J, Suda D, Light G (1986) Beta carotene is associated with the regression of hamster buccal pouch carcinoma and the induction of tumor necrosis factor in macrophages. Biochem Biophys Res Commun 136: 1130-1135.
39. Sies H, Stahl W (1997) Carotenoids and intercellular communication via gap junctions. Int J Vitam Nutr Res 67: 364-367.
40. Hughes DA, Wright AJ, Finglas PM, Peerless AC, Bailey AL, et al. (1997) The effect of beta-carotene supplementation on the immune function of blood monocytes from healthy male nonsmokers. J Lab Clin Med 129: 309-317.
41. Bertram JS, Bortkiewicz H (1995) Dietary carotenoids inhibit neoplastic transformation and modulate gene expression in mouse and human cells. Am J Clin Nutr 62: 1327S-1336S.
42. Hsu YW, Tsai CF, Chang WH, Ho YC, Chen WK, et al. (2008) Protective effects of *Dunaliella salina*--a carotenoids-rich alga, against carbon tetrachloride-induced hepatotoxicity in mice. Food Chem Toxicol 46: 3311-3317.
43. Ben-Amotz A, Levy Y (1996) Bioavailability of a natural isomer mixture compared with synthetic all-trans beta-carotene in human serum. Am J Clin Nutr 63: 729-734.
44. Mokady S, Abramovici A, Cogan U (1989) The safety evaluation of *Dunaliella bardawil* as a potential food supplement. Food Chem Toxicol 27: 221-226.
45. Guerin M, Huntley ME, Olaizola M (2003) *Haematococcus* astaxanthin: applications for human health and nutrition. Trends Biotechnol 21: 210-216.
46. Spolaore P, Joannis-Cassan C, Duran E, Isambert A (2006) Commercial applications of microalgae. J Biosci Bioeng 101: 87-96.
47. Lorenz RT, Cysewski GR (2000) Commercial potential for *Haematococcus* microalgae as a natural source of astaxanthin. Trends Biotechnol 18: 160-167.
48. Miki W (1991) Biological functions and activities of animal carotenoids. Pure Appl Chem 63: 141-146.
49. Naguib YM (2000) Antioxidant activities of astaxanthin and related carotenoids. J Agric Food Chem 48: 1150-1154.
50. Hussein G, Nakagawa T, Goto H, Shimada Y, Matsumoto K, et al. (2007) Astaxanthin ameliorates features of metabolic syndrome in SHR/NDmcr-cp. Life Sci 80: 522-529.
51. Jyonouchi H, Sun S, Tomita Y, Gross MD (1995) Astaxanthin, a carotenoid without vitamin A activity, augments antibody responses in cultures including T-helper cell clones and suboptimal doses of antigen. J Nutr 125: 2483-2492.
52. Fassett RG, Coombes JS (2012) Astaxanthin in cardiovascular health and disease. Molecules 17: 2030-2048.
53. Bertram JS (1999) Carotenoids and gene regulation. Nutr Rev 57: 182-191.
54. Bennedsen M, Wang X, Willén R, Wadström T, Andersen LP (1999) Treatment of *H. pylori* infected mice with antioxidant astaxanthin reduces gastric inflammation, bacterial load and modulates cytokine release by splenocytes. Immunol Lett 70: 185-189.
55. Tso MOM, Lam TT (1996) Method of retarding and ameliorating central nervous system and eye damage, US Patent 5527533.
56. Zhang X, Pan L, Wei X, Gao H, Liu J (2007) Impact of astaxanthin-enriched algal powder of *Haematococcus pluvialis* on memory improvement in BALB/c mice. Environ Geochem Health 29: 483-489.
57. Nishikawa Y, Minenaka Y, Ichimura M (1997) Physiological and biochemical effects of carotenoid (beta-carotene and astaxanthin) on rat. Kashien Daigaku Kiyo 25: 19-25.
58. Spiller GA, Dewell A (2003) Safety of an astaxanthin-rich *Haematococcus pluvialis* algal extract: a randomized clinical trial. J Med Food 6: 51-56.
59. Satoh A, Tsuji S, Okada Y, Murakami N, Urami M, et al. (2009) Preliminary Clinical Evaluation of Toxicity and Efficacy of A New Astaxanthin-rich *Haematococcus pluvialis* Extract. J Clin Biochem Nutr 44: 280-284.
60. Mera Pharmaceuticals Inc. (1999) *Haematococcus pluvialis* and astaxanthin safety for human consumption. Technical Report TR.3005.001.
61. Marazzi G, Cacciotti L, Pelliccia F, Iaia L, Volterrani M, et al. (2011) Long-term effects of nutraceuticals (berberine, red yeast rice, policosanol) in elderly hypercholesterolemic patients. Adv Ther 28: 1105-1113.
62. Schaeffer DJ, Malpas PB, Barton LL (1999) Risk assessment of microcystin in dietary *Aphanizomenon flos-aquae*. Ecotoxicol Environ Saf 44: 73-80.
63. Dashwood R, Guo D (1995) Protective properties of chlorophylls against the covalent binding of heterocyclic amines to DNA in vitro and in vivo. Princess Takamatsu Symp 23: 181-189.
64. Romay C, Armesto J, Ramirez D, González R, Ledon N, et al. (1998) Antioxidant and anti-inflammatory properties of C-phycoerythrin from blue-green algae. Inflamm Res 47: 36-41.
65. Kushak RI, Drapeau C, Van Cott EM, Winter HH (2000) Favorable effect of blue-green algae *Aphanizomenon flos-aquae* on rat plasma lipids. J Am Nutr Assoc 2: 59-65.
66. Miyamoto E, Tanioka Y, Nakao T, Barla F, Inui H, et al. (2006) Purification and characterization of a corrinoid-compound in an edible cyanobacterium *Aphanizomenon flos-aquae* as a nutritional supplementary food. J Agric Food Chem 54: 9604-9607.
67. DeWille JW, Fraker PJ, Romsos DR (1979) Effects of essential fatty acid deficiency, and various levels of dietary polyunsaturated fatty acids, on humoral immunity in mice. J Nutr 109: 1018-1027.
68. Kremer JM, Lawrence DC, Jubiz W (1989) Different doses of fish-oil fatty acid injection in active rheumatoid arthritis: a prospective study on clinical and immunological parameters. Dietary LW3 and LW6 Fatty Acids: Biological Effects and Nutritional Effects and Nutritional Essentiality. Plenum Publishing, New York, USA.
69. Kromhout D (1989) Fish oil consumption and coronary heart disease. Dietary LW3 and LW6 Fatty Acids: Biological Effects and Nutritional Effects and Nutritional Essentiality. Plenum Publishing, New York, USA.
70. Simopoulos AP (1991) Omega-3 fatty acids in health and disease and in growth and development. Am J Clin Nutr 54: 438-463.
71. Hibbeln JR, Salem N Jr (1995) Dietary polyunsaturated fatty acids and depression: when cholesterol does not satisfy. Am J Clin Nutr 62: 1-9.

72. Wright S, Burton JL (1982) Oral evening-primrose-seed oil improves atopic eczema. *Lancet* 2: 1120-1122.
73. Narisawa T, Fukaura Y, Yazawa K, Ishikawa C, Isoda Y, et al. (1994) Colon cancer prevention with a small amount of dietary perilla oil high in alpha-linolenic acid in an animal model. *Cancer* 73: 2069-2075.
74. Smith DL, Willis AL, Nguyen N, Conner D, Zahedi S, et al. (1989) Eskimo plasma constituents, dihomo-gamma-linolenic acid, eicosapentaenoic acid and docosahexaenoic acid inhibit the release of atherogenic mitogens. *Lipids* 24: 70-75.
75. Manoukian R, Citton M, Huerta P, Rhode B, Drapeau C, et al. (1998) Effects of the blue-green algae *Aphanizomenon flos-aquae* (L.) Ralps on human Natural Killer cells. *Phytochemicals: Examining the Health Benefits and Pharmaceutical Properties of Natural Antioxidants and Phytochemicals*. IBC Library Series, Thailand.
76. Ostensvik O, Skulberg OM, Underdal B, Hormazabal V (1998) Antibacterial properties of extracts from selected planktonic freshwater cyanobacteria—a comparative study of bacterial bioassays. *J Appl Microbiol* 84: 1117-1124.
77. Stevens LJ, Zentall SS, Deck JL, Abate ML, Watkins BA, et al. (1995) Essential fatty acid metabolism in boys with attention-deficit hyperactivity disorder. *Am J Clin Nutr* 62: 761-768.
78. Carmichael WW (1997) *The cyanotoxins*. Advances in Botanical Research. Academic Press, London, England.
79. Carmichael WW, Drapeau C, Anderson DM (2000) Harvesting of *Aphanizomenon flos-aquae* Ralps ex Born. & Flah. var. *flos-aquae* (Cyanobacteria) from Klamath Lake for human dietary use. *J Appl Phycol* 12: 585-595.
80. Ciferri O, Tiboni O (1985) The biochemistry and industrial potential of *Spirulina*. *Annu Rev Microbiol* 39: 503-526.
81. Abdulqader G, Barsanti L, Tredici MR (2000) Harvest of *Arthrospira platensis* from Lake Kossorom (Chad) and its household usage among the Kanembu. *J Appl Phycol* 12: 493-498.
82. Ciferri O (1983) *Spirulina*, the edible microorganism. *Microbiol Rev* 47: 551-578.
83. Vonshak A (1997) *Spirulina platensis* (Arthrospira): Physiology, Cell-biology and Biotechnology. Taylor & Francis, London, UK.
84. Gershwin ME, Belay A (2008) *Spirulina* in human nutrition and health. CRC Press, Boca Raton, FL, USA.
85. Belay A, Ota Y, Miyakawa K, Shimamatsu H (1993) Current knowledge on potential health benefits of *Spirulina*. *J Appl Phycol*. 5: 235-241.
86. Becker EW, Jakover B, Luft D, Schmuelling RM (1986) Clinical and biochemical evaluations of the alga *Spirulina* with regard to its application in the treatment of obesity: a double-blind cross-over study. *Nutr Rep Int* 33: 565-574.
87. Takai Y, Hosoyamada Y, Kato T (1991) Effect of water-soluble and water insoluble fractions of *Spirulina* over serum lipids and glucose resistance of rats. *J Jap Soc Nutr Food Sci* 44: 273-277.
88. Iwata K, Inayama T, Kato T (1990) Effects of *Spirulina platensis* on plasma lipoprotein lipase activity in fructose-induced hyperlipidemic rats. *J Nutr Sci Vitaminol (Tokyo)* 36: 165-171.
89. Hernández-Corona A, Nieves I, Meckes M, Chamorro G, Barron BL (2002) Antiviral activity of *Spirulina maxima* against herpes simplex virus type 2. *Antiviral Res* 56: 279-285.
90. Tang G, Suter PM (2011) Vitamin A, Nutrition, and Health Values of Algae: *Spirulina*, *Chlorella*, and *Dunaliella*. *J Pharm Nutr Sci*. 1: 111-118.
91. Schwartz J, Shklar G, Reid S, Trickler D (1988) Prevention of experimental oral cancer by extracts of *Spirulina-Dunaliella* algae. *Nutr Cancer* 11: 127-134.
92. Mishima T, Murata J, Toyoshima M, Fujii H, Nakajima M, et al. (1998) Inhibition of tumor invasion and metastasis by calcium spirulan (Ca-SP), a novel sulfated polysaccharide derived from a blue-green alga, *Spirulina platensis*. *Clin Exp Metastasis* 16: 541-550.
93. Hibbeln JR, Salem N Jr (1995) Dietary polyunsaturated fatty acids and depression: when cholesterol does not satisfy. *Am J Clin Nutr* 62: 1-9.
94. Stevens LJ, Zentall SS, Deck JL, Abate ML, Watkins BA, et al. (1995) Essential fatty acid metabolism in boys with attention-deficit hyperactivity disorder. *Am J Clin Nutr* 62: 761-768.
95. de Caire GZ, de Cano MS, de Mule CZ, Steyerthal N, Piantanida M (1995) Effect of *Spirulina platensis* on glucose, uric acid and cholesterol levels in the blood of rodents. *Intern J Exp Botany* 57: 93-96.
96. Tsuchihashi N, Watanabe T, Takai Y (1987) Effect of *Spirulina platensis* on caecum content in rats. *Bull Chiba Hygiene Coll* 5: 27-30.
97. Archer DL, Glinemann WH (1985) Intestinal infection and malnutrition initiate Acquired Immune Deficiency Syndrome (AIDS). *Nutr Res* 5: 9-19.
98. Watanabe F, Takenaka S, Kittaka-Katsura H, Ebara S, Miyamoto E (2002) Characterization and bioavailability of vitamin B12-compounds from edible algae. *J Nutr Sci Vitaminol (Tokyo)* 48: 325-331.
99. Gilroy DJ, Kauffman KW, Hall RA, Huang X, Chu FS (2000) Assessing potential health risks from microcystin toxins in blue-green algae dietary supplements. *Environ Health Perspect* 108: 435-439.
100. Griffith HW (1998) *Vitamins, herbs, minerals & supplements: the complete guide*. Fisher Books, Tucson, AZ, USA.
101. Bratman S, Kroll D (1999) *Natural health Bible*. Prima Publishing, Rocklin, CA, USA.
102. Borowitzka MA (1999) Commercial production of microalgae: ponds, tanks, tubes and fermenters. *J Biotechnol* 70: 313-321.
103. Liang S, Liu X, Chen F, Chen Z (2004) Current microalgal health food R & D activities in China. *Hydrobiologia* 512: 45-48.